Integrating Asciminib into the Evolving Treatment Landscape of Chronic Myeloid Leukemia: A Canadian Perspective

Five years after the first readout of the ASCEMBL trial, asciminib evidence has rapidly expanded across the chronic myeloid leukemia (CML) treatment landscape. Subsequent studies and growing real-world experience have also clarified its efficacy and tolerability in earlier treatment lines. As the first allosteric inhibitor targeting the BCR::ABL1 myristoyl pocket, asciminib provides a mechanistically distinct approach that may reduce cross-resistance and toxicity associated with ATP-competitive TKIs. At a time when treatment goals in CML emphasize long-term tolerability, quality of life, and the potential for treatment-free remission (TFR), asciminib's unique molecular and clinical profile justify its inclusion in CML treatment considerations. In this expert opinion review, we synthesize emerging clinical and real-world evidence for asciminib and discuss practical considerations for its integration into contemporary CML management, including its potential im-plications for TFR eligibility. We also explore the role of next-generation sequencing in detecting salvageable resistance mutations, the prognostic significance of co-mutations such as ASXL1, and the concept of mutation-guided treatment sequencing. Collectively, these data position asciminib as an established later-line therapy and an emerging frontline option, with the potential to improve long-term treatment sustainability through favorable tolerability and early molecular response kinetics.